检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

77P A study to evaluate the safety, tolerability and efficacy of IBI939 in combination with sintilimab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

Y. Cheng,B. Liu,L. Wu,T. Zhang,K. Wang,L. Miao,J. Wu,H. Wang,J. Fang,X. Li,W. Zhang,Y. Hu,X. Mei,Y. Song,C. Wu,J. Zhu,Y. Xin,Y. Chen, G. Han,J. Ye

Immuno-Oncology and Technology（2022）

引用 0|浏览10
暂无评分
关键词
sintilimab,ibi939,lung,non-small
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要